# Glycine Memory Randomized Trial: What the Evidence Says
Canonical: https://www.migaku.app/guides/glycine-memory-randomized-trial-evidence-review
Category: evidence-review
Summary: Glycine Memory Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed b
Last reviewed: 2026-08-19
Reviewed by: Migaku Evidence Review
# Glycine Memory Randomized Trial: What the Evidence Says

## Quick Answer

Glycine Memory Randomized Trial has 2 source documents in the current Migaku evidence database. The strongest available sources in this first pass are mixed biomedical and public-health sources, so conclusions should be framed as evidence-aware guidance rather than medical advice.

## Key Takeaways

- This page is generated only from sources stored in the Migaku evidence knowledge base.
- Current evidence mix: 1 narrative review, 1 preclinical study.
- Claims should be interpreted with the source type, study design, population, and publication date in mind.
- This article is educational and does not replace care from a qualified clinician.

## Evidence Map

| Source | Evidence type | Level | Date | Identifier |
| --- | --- | ---: | --- | --- |
| Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults | narrative review | 3 | 2026-05-18 | 10.3389/fnut.2026.1775264 |
| Mechanism‐Based Polypharmacy as a Repurposing Strategy: The Case of D‐Cycloserine and Lurasidone | preclinical study | 4 | 2026-06-07 | 10.1111/cts.70624 |

## What The Sources Report

- Aging is characterized by progressive physiological decline, including loss of skeletal muscle mass and function (Sarcopenia), reduced mitochondrial efficiency, and increased oxidative stress, all of which contribute to frailty and diminished quality of life in older adults. [Wang Xiaolan (2026); evidence level 3]
- By the age of 70, individuals may experience a 25%−30% reduction in muscle mass, which is strongly associated with impaired mobility, falls, and loss of independence. [Wang Xiaolan (2026); evidence level 3]
- In bipolar disorder, for instance, combination treatment with lithium and valproate for mania prophylaxis is widely used in clinical practice, even though evidence for this and other maintenance polypharmacy lacks robust scientific backing. [Franzen Avery D. (2026); evidence level 4]
- The risks of polypharmacy are clear and well-known to prescribers and researchers alike, but through intentional mechanistic pairings a rational way forward can be found. [Franzen Avery D. (2026); evidence level 4]

## How To Read This Evidence

Evidence level 1 generally reflects systematic reviews or meta-analyses. Level 2 includes randomized trials, guidelines, or public-health guidance. Level 3 usually reflects observational or narrative-review evidence. Level 4 is weaker or early-stage evidence. The level is a sorting aid, not a final quality grade.

## Practical Interpretation

For glycine memory randomized trial, the current source set is useful for orientation, but it is not yet broad enough for strong claims. Use cautious language and keep conclusions close to the cited sources.

## Limits Of This First Pass

This is a small-batch MVP article. It uses the first ingested sources for this topic and should be expanded with more targeted searches, license review, and human editorial checks before being treated as a definitive review.

## References

- Wang Xiaolan (2026). Glycine and N-acetylcysteine supplementation, with or without exercise, in brain health and functional aging: implications for sarcopenia and frailty in older adults. DOI: 10.3389/fnut.2026.1775264. PMCID: PMC13223053. PMID: 42232577. License: CC BY 4.0. https://pmc.ncbi.nlm.nih.gov/articles/PMC13223053/
- Franzen Avery D. (2026). Mechanism‐Based Polypharmacy as a Repurposing Strategy: The Case of D‐Cycloserine and Lurasidone. DOI: 10.1111/cts.70624. PMCID: PMC13242789. PMID: 42251640. License: https://creativecommons.org/licenses/by-nc/4.0/ http://creativecommons.org/licenses/by-nc/4.0/ This is an open access.... https://pmc.ncbi.nlm.nih.gov/articles/PMC13242789/

## Safety Note

Health information can change, and individual risk depends on medical history, medications, pregnancy status, age, and diagnosis. Talk with a qualified clinician before changing treatment, supplement, or medication routines.